Anti-Human Bcl-xL

Pricing & Details

Product No.B450
Protein
Bcl-xL
Formats AvailableView All
Product Type
Polyclonal Antibody
Alternate Names
Basal Cell Lymphoma-Extra Large
Applications
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
B450-20ug
20 µg
$195.00
In stock
Max:
Min: 1
Step: 1
B450-0.1 mg
0.1 mg
$397.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Data

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Rabbit
Immunogen
Purified Recombinant Human Bcl-xL (>98%)
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Human Basal Cell Lymphoma-Extra Large (Bcl-xL) recognizes Human Bcl-xL. This polyclonal antibody was purified using affinity chromatography.
Background
Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer.1 Bcl-xL is a member of the Bcl-2 family of proteins that are critical regulators of apoptosis.2,3 These can be divided into two classes: those that inhibit apoptosis and those that promote cell death. Bcl-xL is an anti-apoptotic mitochondrial protein related to Bcl-w and the major transcript of the bcl-x gene.4 Its high expression in tumors is correlated with advanced disease and poor prognosis.5 Bcl-xL expression level increases in response to several stimuli such as ionizing radiation and treatment with chemotherapeutic agents.6,7

Antigen Details

Protein
PubMed

References & Citations

1. Lockshin, RA. et al. (2000) Cell Death Differ. 7:2-7.
2. Cory, S. et al. (2003) Oncogene 22:8590-607.
3. Heiser, D. et al. (2004) Exp. Geron. 39:1125-35.
4. Gonzalez-Garcia, M. et al. (1994) Development 120:3033-42.
General Western Blot Protocol
Prod No.
Description
B450
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok